The primary objective of this study is to evaluate the 24-hour spirometric effect (FEV1) of a new drug over a 12-week treatment period in subjects with COPD.

The primary objectives of this study are to evaluate the 12-week safety, antiviral activity and tolerability of this new Hep C drug when given in combination with PEG and RIBA as measured by extended rapid virologic response.